Fed’s Hammack Says Bond Yield Surge Is Not Driven by Inflation Fears 
Gold Holds Near $4,275 as Rising Treasury Yields Fuel Fed Rate Hike Bets 
US Comfortable With Canada Trade Standoff as Import Bans Loom 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
Japan Private-Sector Growth Slows as Domestic Demand Weakens 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Japanese Yen Rebounds as Trump Flags Currency Weakness 
Japanese Bank Stocks Surge as Bond Yields Fuel Rate Hike Bets 
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
Trump, Xi Focus on Trade and AI at White House Summit 
Gold Prices Fall as Treasury Yields Rise on Fed Rate Hike Bets 
Asian Stocks Fall as Surging Bond Yields Rattle Markets 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
RBI Uses $10 Billion Currency Swaps to Drain Excess Rupee Liquidity 
US Stock Futures Fall as Treasury Yields Surge Ahead of Trump-Xi Summit 
Add as a preferred source on Google
China’s WuXi AppTec has signed an agreement to sell its gene therapy manufacturing arm, WuXi Advanced Therapies, to U.S.-based Altaris LLC, following mounting restrictions on Chinese firms in the United States over national security concerns. The deal also includes Oxford Genetics in the UK.
WuXi AppTec Sells Gene Therapy Unit Amid US Restrictions
The Chinese company WuXi AppTec announced on Tuesday that its subsidiaries have inked a contract with the private equity firm Altaris LLC, which is based in the United States, for the sale of its cell and gene therapy manufacturing unit, WuXi Advanced Therapies, for an amount that has not been disclosed.
Due to worries regarding national security, the corporation, along with other Chinese businesses, has been at the focus of new regulations that have been enacted in the United States with the intention of restricting their businesses in the United States, Investing.com shares.
US Legislation Targets Chinese Companies Over National Security Concerns
In September, the House of Representatives of the United States of America enacted a bill that would bar the federal government from entering into contracts with specified companies and those that do business with those companies.
The laws are intended to protect the personal health and genetic information of Americans from foreign adversaries.
Shift in US Pharma and Biotech Supply Chains
Additionally, they intend to encourage pharmaceutical and biotechnology businesses in the United States to reduce their reliance on China for a variety of activities, including the manufacturing of medicinal ingredients and early research.
The United Kingdom-based operating company of the WuXi ATU business, Oxford Genetics, will be sold to Altaris LLC, according to a statement made by WuXi.
Altaris declined to comment further than the information that was provided, while WuXi AppTec did not react to a request for comment made by Reuters by the company.
